Q-omics provides the consensus-scored ZNF687-AS1 profile across patient tissues and cancer cell-line models. ZNF687-AS1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZNF687-AS1 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, ZNF687-AS1 RNA expression shows 16,088 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and BLCA as cancer lineages where ZNF687-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF687-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF687-AS1 survival associations across molecular data types. ZNF687-AS1 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF687-AS1 RNA expression–survival associations across cancer types. High ZNF687-AS1 expression shows unfavorable associations in ACC, LGG, MESO and UCEC, but favorable associations in OV and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZNF687-AS1 RNA expression.
This table summarizes ZNF687-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF687-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF687-AS1 shows lower tumor expression in KIRC and KICH and higher tumor expression in BLCA, HNSC, LUAD and LIHC. The BLCA box plot shows higher ZNF687-AS1 RNA expression in tumor versus normal tissue (log2 FC = +1.121, t-test p < 0.001).
This table shows molecular features associated with ZNF687-AS1 in patient tissues and cancer cell lines. In patient samples, ZNF687-AS1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
